FILE - The Pfizer logo is displayed at the company's headquarters, Feb. 5, 2021, in New York. Sales of Pfizer’s COVID-19 vaccine and treatment in the second quarter propelled the pharmaceutical giant ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...

• Spikevax and Comirnaty are brand names for the Moderna and Pfizer COVID-19 vaccines, respectively. The drug formulation is the same for the branded and non-branded vaccines. • The non-branded ...

Pfizer’s BioNTech-partnered COVID-19 vaccine Comirnaty and its antiviral pill Paxlovid are destined to reap many billions in 2022, but the company’s first-quarter pandemic haul may come in lighter ...

Pfizer Inc. (NYSE:PFE) is included among the 13 Best January Dividend Stocks to Invest in. Pfizer Inc. (NYSE:PFE) is among ...

Sales of Pfizer’s COVID-19 vaccine and treatment in the second quarter propelled the pharmaceutical giant to the largest quarterly sales in its history. The coronavirus vaccine Comirnaty brought in $8 ...